We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+16.35%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$995M
AUM Growth
-$103M
Cap. Flow
-$165M
Cap. Flow %
-16.56%
Top 10 Hldgs %
79.85%
Holding
33
New
6
Increased
13
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$29.1M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$25.9M
3
CLDX icon
Celldex Therapeutics
CLDX
+$19.9M
4
PACB icon
Pacific Biosciences
PACB
+$19.6M
5
CSII
Cardiovascular Systems, Inc.
CSII
+$9.17M

Top Sells

Rank Stock Value
1
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$87.3M
2
UTHR icon
United Therapeutics
UTHR
+$58.5M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$48M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$43.1M
5
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$34.9M

Sector Composition

Rank Sector Weight
1 Healthcare 83.48%
2 Technology 0.16%
3 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMPR
26
DELISTED
IMPRIVATA, INC COM
IMPR
$1.57M 0.16%
+95,759
New +$1.44M
BIOL
27
DELISTED
Biolase, Inc.
BIOL
$1.16M 0.12%
+53
New +$1.29M
EHTH icon
28
eHealth
EHTH
$43.8M
$67K 0.01%
5,242
-47,658
-90% -$576K
PLX icon
29
Protalix BioTherapeutics
PLX
$183M
– –
-564,375
Closed -$10M
SUPN icon
30
Supernus Pharmaceuticals
SUPN
$2.65B
– –
-3,566,923
Closed -$43.1M
PTX
31
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-326,148
Closed -$34.9M
HPTX
32
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
– –
-1,901,930
Closed -$87.3M
ANAC
33
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
– –
-830,151
Closed -$48M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Consonance Capital Management held 33 positions worth $995M, down 9.4% from $1.1B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Consonance Capital Management withdrew a net $165M in Q2 2015, closing 5 positions and reducing 8 holdings. Its most notable exit was HYPERION THERAPEUTICS INC COM STK (DE), an estimated $87.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 70% a quarter earlier, followed by Technology and Financials.

Against the trend, Consonance Capital Management opened a new position in Clovis Oncology, Inc. worth $26.6M.

  • Consonance Capital Management's largest Q2 2015 buy was Clovis Oncology, Inc.: 303,131 shares worth $26.6M.
  • Consonance Capital Management added most to Eagle Pharmaceuticals, Inc. in Q2 2015, an estimated $29.1M increase.
  • Consonance Capital Management's biggest Q2 2015 reduction was United Therapeutics, cutting an estimated $58.5M.
  • Consonance Capital Management fully exited HYPERION THERAPEUTICS INC COM STK (DE) in Q2 2015, selling an estimated $87.3M.
  • Consonance Capital Management's ten largest holdings make up 80% of its $995M portfolio in Q2 2015.
  • Consonance Capital Management opened 6 new positions and closed 5 in Q2 2015.
  • Consonance Capital Management's portfolio value fell 9.4% quarter-over-quarter to $995M.

Based on Consonance Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.